Sugi Predict

Sugi Predict / Compounds / SCHEMBL737361

SCHEMBL737361

SCHEMBL737361

CC(C)(C)OC(=O)C1CCNC(=O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ GAA P10253 1/20 0.33
▸ BUB1 O43683 1/20 0.32
▸ CASP3 P42574 1/20 0.32
▸ DDB1 Q16531 3/20 0.32
▸ CRBN Q96SW2 3/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SLC5A1 P13866 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31
▸ HDAC1 Q13547 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.31
▸ PLAT P00750 1/20 0.30
▸ HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15565329 0.90 KMT2A (0.36) MAPK1HRH3KDM4EMAPTGAA
SCHEMBL757453 0.84 SLC5A1 (0.35) SLC5A1CCR2
SCHEMBL20487411 0.82 HRH3 (0.34) HRH3KMT2A
SCHEMBL28009383 0.82 MAPK1 (0.39) MAPK1HRH3GAABUB1SLC5A1
SCHEMBL2153275 0.82 BRD4 (0.43) KDM4EKMT2A
SCHEMBL19322915 0.79 CCR2 (0.35) KMT2ASLC5A1CCR2
SCHEMBL1467839 0.78 ALDH1A1 (0.43) KDM4EMAPTGAAKMT2AHPGD
SCHEMBL20300486 0.77 KMT2A (0.30) KMT2A
Hydrochloric Acid SCHEMBL3328736 0.77 TSHR (0.43) MAPK1HRH3KMT2APLATHPGD
SCHEMBL16892260 0.76 KMT2A (0.36) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102464605-B Preparation method of 4-nitro-piperidine derivative WUXI APPTEC CO LTD 2014-12-10 — — CN claimed
CN-102464605-A Process for the preparation of 4-nitro-piperidine derivatives WUXI APPTEC CO LTD 2012-05-23 — — CN claimed
US-12497392-B2 EP300/CBP inhibitor HINOVA PHARMACEUTICALS INC. (CN) 2025-12-16 — — US disclosed
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
CN-112574189-B EP300/CBP inhibitor 海创药业股份有限公司 2024-05-31 — — CN disclosed
US-20230027088-A1 EP300/CBP INHIBITOR HINOVA PHARMACEUTICALS INC. (CN) 2023-01-26 — — US disclosed
EP-4043458-A1 EP300/CBP INHIBITOR Hinova Pharmaceuticals Inc. (CN) 2022-08-17 — — EP disclosed
US-11414410-B2 Inhibitors of protein kinases ALEXION PHARMACEUTICALS, INC. (US) 2022-08-16 — — US disclosed
CN-108289886-B Ion channel inhibiting compounds, pharmaceutical formulations and uses 安华赛公司 2022-01-28 — — CN disclosed
WO-2021057915-A1 EP300/CBP INHIBITOR 成都海创药业有限公司 2021-04-01 — — WO disclosed
CN-112574189-A EP300/CBP inhibitor 海创药业股份有限公司 2021-03-30 — — CN disclosed
US-20030171400-A1 Heterocyclic side chain containing metalloprotease inhibitors PROCTER & GAMBLE COMPANY, THE 2003-09-11 — — US disclosed
US-20030139414-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors THE PROCTER & GAMBLE COMPANY 2003-07-24 — — US disclosed
EP-1325910-A1 ALIPHATIC NITROGENOUS FIVE-MEMBERED RING COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-07-09 — — EP disclosed
CN-1425004-A N-substituted metal proteinase inhibitor with heterocyclic side chain PROCTER & GAMBLE (US) 2003-06-18 — — CN disclosed
CN-1418193-A heterocyclic side chain containing metalloprotease inbibitors PROCTER & GAMBLE (US) 2003-05-14 — — CN disclosed
EP-1265864-A1 HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 — — EP disclosed
EP-1265863-A1 HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-12-18 — — EP disclosed
WO-2001070690-A1 HETEROCYCLIC SIDE CHAIN CONTAINING METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 — — WO disclosed
WO-2001070691-A1 HETEROCYCLIC SIDE CHAIN CONTAINING, N-SUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497392-B2 EP300/CBP inhibitor EP300, MLLT1, CREBBP MAPK1 435/4885HRH3 1855/4885KDM4E 143/4885
US-20030139414-A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors MME, MMP2, MMP9 MAPK1 2791/4885HRH3 995/4885KDM4E 1323/4885
US-20230027088-A1 EP300/CBP INHIBITOR EP300, MLLT1, CREBBP MAPK1 435/4885HRH3 1855/4885KDM4E 143/4885
US-11414410-B2 Inhibitors of protein kinases MAP3K1, MAP3K20, MAP3K2 MAPK1 17/4885HRH3 2978/4885KDM4E 1016/4885
US-20030171400-A1 Heterocyclic side chain containing metalloprotease inhibitors SERPINB1, ADAM17, TMPRSS15 MAPK1 1934/4885HRH3 1377/4885KDM4E 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.